{"title":"Emerging research themes in drug resistance in osteosarcoma: a 25-year bibliometric and visualized analysis.","authors":"Xin He, Wanquan Cao, Jialun Wang, Hang Zhong","doi":"10.1007/s00210-025-04683-x","DOIUrl":null,"url":null,"abstract":"<p><p>Drug resistance is a major barrier to effective treatment in osteosarcoma, the most common primary malignant bone tumor in adolescents and young adults. Although advancements in surgical techniques and chemotherapeutic regimens have improved local control, long-term survival rates remain stagnant, largely due to intrinsic and acquired resistance mechanisms. This study aimed to perform a comprehensive bibliometric and visualized analysis of global research trends in osteosarcoma drug resistance from 2000 to 2025. A total of 927 English-language articles and reviews were retrieved from the Web of Science Core Collection and analyzed using VOSviewer, CiteSpace, Scimago Graphica, and Charticulator. Our findings reveal a steady increase in annual publications, with China and the USA leading in productivity and academic influence, respectively. Thematic evolution in this field has shifted from classical mechanisms such as P-glycoprotein and apoptosis to emerging areas including autophagy, EMT, non-coding RNAs, tumor microenvironment remodeling, and nanomedicine. Recent keyword and reference burst analyses suggest growing interest in immunotherapy, ferroptosis, metabolic vulnerabilities (e.g., methionine dependence), and exosome-mediated resistance pathways. This study provides a macroscopic view of the knowledge landscape in osteosarcoma drug resistance and highlights the importance of integrating interdisciplinary approaches such as spatial omics, immunometabolism, and precision drug delivery into future research and clinical translation. These insights may inform the development of novel and personalized therapeutic strategies to improve outcomes for osteosarcoma patients.</p>","PeriodicalId":18876,"journal":{"name":"Naunyn-Schmiedeberg's archives of pharmacology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Naunyn-Schmiedeberg's archives of pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00210-025-04683-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Drug resistance is a major barrier to effective treatment in osteosarcoma, the most common primary malignant bone tumor in adolescents and young adults. Although advancements in surgical techniques and chemotherapeutic regimens have improved local control, long-term survival rates remain stagnant, largely due to intrinsic and acquired resistance mechanisms. This study aimed to perform a comprehensive bibliometric and visualized analysis of global research trends in osteosarcoma drug resistance from 2000 to 2025. A total of 927 English-language articles and reviews were retrieved from the Web of Science Core Collection and analyzed using VOSviewer, CiteSpace, Scimago Graphica, and Charticulator. Our findings reveal a steady increase in annual publications, with China and the USA leading in productivity and academic influence, respectively. Thematic evolution in this field has shifted from classical mechanisms such as P-glycoprotein and apoptosis to emerging areas including autophagy, EMT, non-coding RNAs, tumor microenvironment remodeling, and nanomedicine. Recent keyword and reference burst analyses suggest growing interest in immunotherapy, ferroptosis, metabolic vulnerabilities (e.g., methionine dependence), and exosome-mediated resistance pathways. This study provides a macroscopic view of the knowledge landscape in osteosarcoma drug resistance and highlights the importance of integrating interdisciplinary approaches such as spatial omics, immunometabolism, and precision drug delivery into future research and clinical translation. These insights may inform the development of novel and personalized therapeutic strategies to improve outcomes for osteosarcoma patients.
骨肉瘤是青少年和年轻人最常见的原发性恶性骨肿瘤,耐药是骨肉瘤有效治疗的主要障碍。尽管手术技术和化疗方案的进步改善了局部控制,但长期生存率仍然停滞不前,主要是由于内在和获得性耐药机制。本研究旨在对2000年至2025年全球骨肉瘤耐药研究趋势进行全面的文献计量和可视化分析。从Web of Science核心馆藏中检索到927篇英文文章和评论,并使用VOSviewer、CiteSpace、Scimago Graphica和Charticulator进行分析。我们的研究结果显示,中国和美国的年度出版物稳步增长,分别在生产力和学术影响力方面处于领先地位。该领域的主题演变已经从p -糖蛋白和细胞凋亡等经典机制转向新兴领域,包括自噬、EMT、非编码rna、肿瘤微环境重塑和纳米医学。最近的关键词和参考分析表明,人们对免疫治疗、铁中毒、代谢脆弱性(如蛋氨酸依赖)和外泌体介导的耐药途径的兴趣越来越大。本研究提供了骨肉瘤耐药知识景观的宏观视图,并强调了将跨学科方法(如空间组学,免疫代谢和精确给药)整合到未来研究和临床转化中的重要性。这些见解可能为开发新的个性化治疗策略提供信息,以改善骨肉瘤患者的预后。
期刊介绍:
Naunyn-Schmiedeberg''s Archives of Pharmacology was founded in 1873 by B. Naunyn, O. Schmiedeberg and E. Klebs as Archiv für experimentelle Pathologie und Pharmakologie, is the offical journal of the German Society of Experimental and Clinical Pharmacology and Toxicology (Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, DGPT) and the Sphingolipid Club. The journal publishes invited reviews, original articles, short communications and meeting reports and appears monthly. Naunyn-Schmiedeberg''s Archives of Pharmacology welcomes manuscripts for consideration of publication that report new and significant information on drug action and toxicity of chemical compounds. Thus, its scope covers all fields of experimental and clinical pharmacology as well as toxicology and includes studies in the fields of neuropharmacology and cardiovascular pharmacology as well as those describing drug actions at the cellular, biochemical and molecular levels. Moreover, submission of clinical trials with healthy volunteers or patients is encouraged. Short communications provide a means for rapid publication of significant findings of current interest that represent a conceptual advance in the field.